GPX2 is a key antioxidant enzyme involved in the detoxification of reactive oxygen species (ROS), which are known mediators of cisplatin- and 5-FUinduced cytotoxicity [17,18,19,20]

Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals

A peptide's half-life the time it takes for half the active compound to be cleared from your bloodstream determines how often it needs to be administered, how quickly it reaches steady state, and how long its effects persist after your last dose
The drug was described as well tolerated at the dose and duration tested
Together with zinc, selenium, and B vitamins, a complete cycle is created: absorption, production, and renewal